All

Communication Can Mean More to Hypersomnia Patients Than a Label

How evolving diagnoses and unclear terminology can undermine patient trust—and what clinicians can do about it.

All

Quantifying IH Requires More Than Sleep Latency—Here’s What to Try Instead

Measuring sleep inertia, vigilance lapses, and other symptoms with these tools can give sleep physicians trackable data for patients with idiopathic hypersomnia.

All

Harmony Highlights Orexin-2 Agonist and Pitolisant Advances

Harmony reveals new data showing pitolisant's safety at five times the highest labeled dose of WAKIX, along with updates on its orexin-2 agonist and long-term efficacy of pitolisant in IH.

Centessa Appoints Neuropsychiatrist as Chief Medical Officer

Jan 9, 2025 | Recruiting & Hiring

The new CMO brings over 30 years of experience in neuroscience and drug development to Centessa as it advances its orexin receptor 2 agonist portfolio.

Jazz Pharmaceuticals CEO to Retire, Succession Search Underway

Dec 17, 2024 | Recruiting & Hiring

Bruce Cozadd, co-founder, chairperson, and CEO of Jazz, announced plans to retire as CEO upon the appointment of a successor by the end of 2025.

Meeting to Tackle Drug Development Challenges for Idiopathic Hypersomnia

Nov 26, 2024 | Idiopathic Hypersomnia

The Illuminate Hypersomnia Adjunct Scientific Meeting on Feb 13, 2025, will address challenges in idiopathic hypersomnia drug development.

Survey Reveals Power of Social Connections for Narcolepsy and IH Patients

Nov 22, 2024 | Idiopathic Hypersomnia, Narcolepsy

A global survey reveals that peer connections significantly improve support and adjustment for individuals with narcolepsy and idiopathic hypersomnia.

Centessa Launches Phase 2 Trial of ORX750 for Narcolepsy and IH

Nov 14, 2024 | Emerging Compounds

Centessa Pharmaceuticals has initiated a phase 2 trial of ORX750, an oral orexin receptor 2 agonist designed to treat narcolepsy type 1, type 2, and idiopathic hypersomnia.

Centessa Prioritizes Orexin Agonist Program Following Positive Data

Nov 14, 2024 | Emerging Compounds

Centessa Pharmaceuticals discontinues SerpinPC, an investigational hemophilia B therapy, to reallocate resources to its orexin receptor program.

Avadel’s Narcolepsy Treatment Lumryz Brings in $50 Million in Q3

Nov 13, 2024 | Narcolepsy

During the quarter, Lumryz saw increased patient uptake, expanded to pediatric use, and secured a legal victory affirming its clinical superiority, as the company continues its phase 3 trial in idiopathic hypersomnia.

Narcolepsy Insights from Alkermes Presented at Psych Congress and NEI Congress

Nov 7, 2024 | Emerging Compounds

Alkermes’ presentations feature research on its investigational treatment ALKS 2680 in narcolepsy and insights on the burden of living with the condition.

Jazz Hits Record Q3 Revenue with Strong Growth in Sleep Portfolio

Nov 6, 2024 | Pharmaceuticals

Jazz Pharmaceuticals reported record third-quarter 2024 revenues of over $1.05 billion, with strong performance from its sleep portfolio.

Definitive Merger Agreement Reached Between NLS and Kadimastem

Nov 4, 2024 | Emerging Compounds

The companies will combine to focus on advancing NLS’ orexin platform and Kadimastem’s cell therapy program.

Jazz Presents New Phase 4 Data on Xywav’s Impact on Narcolepsy and IH

Nov 1, 2024 | Pharmaceuticals

Top-line results show improvements on excessive daytime sleepiness and key polysomnography outcomes.

Harmony’s Wakix Surpasses $2B in Revenue, Data Shows Promise for IH Treatment

Oct 30, 2024 | Pharmaceuticals

Wakix surpassed $2 billion in cumulative revenue since its 2019 launch for adult narcolepsy, with Harmony on track to submit a supplemental new drug application for idiopathic hypersomnia in Q4.

Alkermes Eyes Completion of Phase 2 Narcolepsy Studies in 2025

Oct 28, 2024 | Emerging Compounds

Alkermes’ Q3 update reveals progress for ALKS 2680, an orexin 2 receptor agonist aimed at treating narcolepsy and idiopathic hypersomnia, with phase 2 trial completions expected in 2025.

What Exactly Is Software as a Medical Device?

Oct 16, 2024 | Connected Care

With increasing FDA clearances for standalone software in sleep medicine, “software as a medical device” is becoming a key term. Experts explain what SaMD entails and explore its unique advantages and challenges.